Biogen (BIIB) Tops Q2 EPS by $1.12; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St futures rise on Mideast deal optimism; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Biogen's (BIIB) "P&L Remains Challenged", Focus on CLARITY-AD - BMO Maintains Stock at Market Perform
July 20, 2022 7:53 AM EDTBMO Capital analyst Evan David Seigerman reiterated a Market Perform rating and $217.00 price target on Biogen (NASDAQ: BIIB), following the company's most recent quarterly report.
The analyst comments: "Good enough quarter with a top- and bottom-line beat, but all that really... More
